United Therapeutics Corp. (NASDAQ:UTHR) Director Christopher Causey sold 1,500 shares of the stock on the open market in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $73.11, for a total transaction of $109,665.00. Following the sale, the director now directly owns 733 shares of the company’s stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Separately, analysts at Guggenheim raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $61.00 to $69.00 in a research note to investors on Tuesday, July 30th. They now have a “neutral” rating on the stock. Finally, analysts at Standpoint Research downgraded shares of United Therapeutics Corp. (NASDAQ:UTHR) from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, July 30th.
Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $63.10.
United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.67% on Friday, hitting $73.67. The stock had a trading volume of 316,447 shares. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $76.95. The stock’s 50-day moving average is $72.63 and its 200-day moving average is $65.96. The company has a market cap of $3.678 billion and a price-to-earnings ratio of 12.79.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 24.4% on a year-over-year basis. On average, analysts predict that United Therapeutics Corp. will post $5.99 earnings per share for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.